Edwards Lifesciences CEO Mike Mussallem has a unique and long-standing perspective of what the medtech industry should be and do. In over two decades, he has built the structural heart disease and critical care monitoring company into one of the global medtech industry’s most effective innovators. That legacy is sure to last after his retirement as CEO in spring 2023.
Mike Mussallem has a long memory and a hold on detail from history as if it were yesterday. He recalls the personal dilemmas he had on deciding whether or not to close research programs – some of the “smaller” decisions a CEO must make – just as readily as how he felt during the milestone moments of Edwards Lifesciences Corp.’ evolution.
Those started in 2000, when Edwards Lifesciences Corp. was spun out from Baxter Healthcare Corp.. That was a ground-breaking...
A scale-up strategy is the missing link in the UK devices industry, claims business research organization CPI. Own brand and contract medical manufacturer and packaging company Pennine Healthcare, and longstanding medical device CDMO Renfrew Group International, give their take on the environment for manufacturers and the opportunities for strengthening the industry base.
Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.
With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.
Compliance with greenhouse gas reduction targets is not optional for medtech businesses who, besides the bigger picture, have their own sustainability to think of. Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation. In the EU, the MDR is also having an effect on innovation strategies.
Devices granted De Novo marketing authorization by the US FDA. Data derived from FDA.gov Updated weekly.
PMA supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
Mergers and acquisitions in the medical device, diagnostics and digital health sectors. Data derived from Citeline’s Meddevicetracker.
